<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PAPAVERINE HYDROCHLORIDE</span><br/>(pa-pav'er-een)<br/><span class="topboxtradename">Cerespan, </span><span class="topboxtradename">Genabid, </span><span class="topboxtradename">Pavabid, </span><span class="topboxtradename">Pavased, </span><span class="topboxtradename">Pavatyme, </span><span class="topboxtradename">Paverolan<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">nonnitrate vasodilator</span><br/><b>Prototype: </b>Hydralazine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg sustained release capsule; 30 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Exerts nonspecific direct spasmolytic effect on smooth muscles unrelated to innervation. Action is especially pronounced on
         coronary, cerebral, pulmonary, and peripheral arteries when spasm is present.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acts directly on myocardium, depresses conduction and irritability, and prolongs refractory period. Stimulates respiration
         by action on carotid and aortic body chemoreceptors.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Primarily for relief of cerebral and peripheral ischemia associated with arterial spasm and MI complicated by arrhythmias.
         Also visceral spasm as in ureteral, biliary, and GI colic.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Impotence, cardiac bypass surgery.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Parenteral use in complete AV block. Safe during pregnancy (category C) or lactation is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Glaucoma; myocardial depression; angina pectoris; recent stroke.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Cerebral and Peripheral Ischemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100300 mg 35 times/d; 150 mg sustained release q812h <span class="rdroute">IM/IV</span> 30120 mg q3h as needed<br/><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span> 6 mg/kg/24 h divided into 4 doses<br/><br/><span class="indicationtitle">Impotence</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 0.537.5 mg injected into the corpus cavernosum of the penis as needed for erection<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with or following meals; give milk or prescribed antacid to reduce possibility of nausea.</li>
<li>Ensure that sustained release form is not chewed or crushed. Must be swallowed whole.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intramuscular</span><ul>
<li>Aspirate carefully before injecting IM to avoid inadvertent entry into blood vessel, and administer slowly.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted or diluted in an equal volume of sterile water for injection.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give slowly over 12 min. <small>AVOID</small> rapid injection.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> General discomfort, facial flushing, sweating, weakness, coma. <span class="typehead">CNS:</span> Dizziness, drowsiness, headache, sedation. <span class="typehead">CV:</span> Slight rise in BP, paroxysmal tachycardia, transient ventricular ectopic rhythms, AV block, arrhythmias. <span class="typehead">GI:</span> Nausea, anorexia, constipation, diarrhea, abdominal distress, dry mouth and throat, <span class="speceff-life">hepatotoxicity</span> (jaundice, eosinophilia, abnormal liver function tests); with rapid IV administration. <span class="typehead">Respiratory:</span> Increased depth of respiration, <span class="speceff-life">respiratory depression, fatal apnea</span>. <span class="typehead">Skin:</span> Pruritus, skin rash. <span class="typehead">Special Senses:</span> Diplopia, nystagmus. <span class="typehead">Urogenital:</span> Priapism. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease <b>levodopa</b> effectiveness; <b>morphine</b> may antagonize smooth muscle relaxation effect of papaverine. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Duration:</span> 6 h regular tablets; 12 h sustained release. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine chiefly as metabolites. <span class="typehead">Half-Life:</span> 90 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor pulse, respiration, and BP in patients receiving drug parenterally. If significant changes are noted, withhold medication
            and report promptly to physician.
         </li>
<li>Lab tests: Perform liver function and blood tests periodically. Hepatotoxicity (thought to be a hypersensitivity reaction)
            is reversible with prompt drug withdrawal.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician if any adverse effect persists or if GI symptoms, jaundice, or skin rash appear. Liver function tests may
            be indicated.
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known. Alcohol may increase drowsiness
            and dizziness.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>